EU regulator approves injectable HIV drug that experts say could help stop transmission
In a statement on Friday, the EU drug regulator said its evaluations of lenacapavir, sold as Yeytuo in Europe by Gilead Sciences, showed the drug is 'highly effective' and 'considered to be of major public health interest.' Once the regulator's guidance is accepted by the European Commission, the authorization is valid in all 27 EU member countries as well as Iceland, Norway and Liechtenstein.
Last year, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping transmission in both women and men.
Winnie Byanyima, executive director of the U.N. AIDS agency, has said the drug 'could change the trajectory of the HIV epidemic' if it is made available to everyone who needs it.
In June, the U.S. Food and Drug Administration authorized lenacapavir to prevent HIV. Earlier this month, the World Health Organization recommended countries offer the drug as an additional option to people at risk of the virus.
Condoms help guard against HIV infection if used properly. Other medication aimed at preventing HIV include daily pills that people can take and another injectable drug called cabotegravir, which is given every two months. Lenacapavir's six-month protection makes it the longest-lasting type, an option that could attract people wary of more visits to health clinics or stigma from taking daily pills.
Critics have raised concerns, however, that lenacapavir may not be made widely enough available to stop global outbreaks of HIV. Drugmaker Gilead has said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates — mostly in Africa, Southeast Asia and the Caribbean.
But it has excluded nearly all of Latin America, where rates are far lower but increasing, sparking concern the world is missing a critical opportunity to stop the disease.
Last year, there were about 630,000 AIDS deaths worldwide and more than 40 million people are estimated to have HIV, according to UNAIDS.
UNAIDS chief Byanyima has previously suggested the U.S. President Donald Trump make a deal with Gilead to produce and license its 'magical' prevention drug lenacapavir across the world to the millions of people who need it.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
8 minutes ago
- BBC News
RSV vaccine cuts hospital risk for newborn babies, research shows
Newborn babies are 80% less likely to be hospitalised with a life-threatening virus if their mother has been vaccinated in pregnancy, new research has found. Respiratory syncytial virus (RSV) is one of the leading causes of bronchiolitis and pneumonia in babies under six months old.A RSV immunisation programme was launched last year for women over 28 weeks pregnant, with around half of those eligible taking up the jab. Public Health Scotland said the programme resulted in 228 fewer babies under three months old being admitted to hospital with serious infection. RSV usually only has mild symptoms, but it can lead to breathing problems in the most vulnerable vaccine is offered to prevent babies contracting the virus in the first six months of their lives – the period when they're most at risk of severe illness. Public Health Minister Jenni Minto said: "RSV can be life-threatening for newborn infants, that is why it is so positive to see this evidence of the impact of the maternal RSV vaccine."I strongly encourage all pregnant women who are offered the vaccine to take up the offer in order to protect their newborn babies."The vaccine, which is also offered to elderly people, resulted in a 62% reduction in RSV-related hospitalisations among the eligible 75-79 age group.
The Independent
38 minutes ago
- The Independent
Full-fat milk vs low-fat milk: Study finally reveals which is healthier for your heart
A decades-long study has finally revealed how healthy full-fat and low-fat milk are, with researchers concluding that one is safer for your heart. Experts analysed three decades of health data and found the fat level of milk influenced a person's risk of dying of heart disease. The study published in the The American Journal of Clinical Nutrition used data from three cardiovascular health screenings conducted between 1974 and 1988. Researchers in Norway tracked the data of 73,860 individuals, with an average age of 41, over 33 years and recorded 26,393 deaths, including 8,590 from cardiovascular disease. They found those who drank full-fat milk had a higher mortality risk in than those who drank low-fat milk. Researchers were able to make this comparison due to a unique historical context. In the 1970s, most people in Norway drank whole milk, but by the 1980s more people drank low-fat milk. This meant researchers were able to investigate the long-term health consequences of drinking both of these milk types. Those who drank the most milk in the study had a 22 per cent increased risk of all-cause mortality and a 12 per cent increased risk of death from cardiovascular disease in comparison to those who drank the least. But further analysis revealed whole milk in particular was driving this increased risk of death. When researchers compared full-fat and low-fat milk and adjusted for how much they drank, they found consuming low-fat milk was associated with a 11 per cent lower mortality risk and a 7 per cent lower risk of cardiovascular disease than consuming whole milk. The findings remained consistent even after excluding early deaths or participants with pre-existing conditions. However, low-fat milk drinkers tended to be females, have higher education and not smoke, in comparison to whole fat milk drinkers who frequently reported being current smokers. Study authors concluded: 'Associations between milk intake and cardiovascular disease and all-cause mortality varied by type of milk, with positive associations found for whole milk and a modestly inverse association with ischemic heart disease and all-cause mortality was found for low-fat milk when compared with whole milk.' The results are in line with current NHS health advice. Most of the fat in milk and dairy foods is saturated fat which when eating in large amounts can contribute to weight gain, the NHS explains. A diet high in saturated fat can also lead to raised levels of cholesterol in the blood, increasing the risk of having a heart attack or a stroke.
Reuters
39 minutes ago
- Reuters
Focus: Trump, pharma industry discuss boosting medicine spending abroad to cut US prices, sources say
NEW YORK, Aug 7 (Reuters) - The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt "most favored nation" pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being "ripped off." The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America - the industry's main lobby group - has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. "Prices can come down in the United States without being increased in other countries, and we can still get innovation," she said. Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. "This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it," the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. "There's a big push from the administration to drive up prices outside the U.S.," the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca (AZN.L), opens new tab, Bayer ( opens new tab and Novo Nordisk ( opens new tab signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. "It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction," Kaltenboeck said, "and it doesn't make much sense for them politically."
